Active substance
Ipratropium
- SFDA 9
- US FDA 33
- Health Canada 9
- US price lines 7
- NHS prices 4
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ATROSOL 250 mcg/2 ml nebuliser solution | 125 µ/ml | Nebuliser solution · Inhalation use | 21 Ampoule | SAR 27.55 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| ATROSOL 250 mcg/ml nebuliser solution | 250 µ/ml | Nebuliser solution · Inhalation use | 21 Vial | SAR 41.20 | Generic · Prescription | Pharmaceutical Solution Industries (PSI) | Valid |
| ATROVENT 250MCG-2ML UDV (SOLUTION FOR INHALATION) | 0.125 mg/ml | inhalation solution · Inhalation use | 20 Vial | SAR 27.60 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
| ATROVENT 500MCG-2ML UDV (SOLUTION FOR INHALATION) | 0.25 mg/ml | Nebuliser solution · Inhalation use | 20 Vial | SAR 42.15 | NCE · Prescription | BOEHRINGER INGELHEIM | Valid |
| ATROPULM 250MCG-ML SOLUTION FOR INHALATION | 0.25 mg/ml | Nebuliser solution · Inhalation use | 1 Bottle | SAR 10.00 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| ATROPULM 500MCG-2ML SOLUTION FOR INHALATION | 0.5 mg/ml | Nebuliser solution · Inhalation use | 10 Ampoule | SAR 21.80 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Withdrawn by MAH · Not Marketed |
| ATROVENT 0.02MG-METERED DOSE INHALER | 0.02 mg | Powder · Inhalation use | 1 Inhaler | SAR 48.80 | NCE · Prescription | BOEHRINGER INGELHEIM | Withdrawn by MAH · Not Marketed |
| ATROVENT 250MCG-2ML UDV (SOLUTION FOR INHALATION) | 0.125 mg/ml | Nebuliser solution · Inhalation use | 20 Vial | SAR 33.75 | NCE · Prescription | BOEHRINGER INGELHEIM | Withdrawn by MAH · Not Marketed |
| ATROVENT 500MCG-2ML UDV (SOLUTION FOR INHALATION) | 0.25 mg/ml | Nebuliser solution · Inhalation use | 20 Vial | SAR 51.50 | NCE · Prescription | BOEHRINGER INGELHEIM | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS)-LONG-TERM ORAL ANTIBIOTIC TREATMENT; ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD); SICKLE CELL DISEASE - ACS MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | RITEDOSE CORP | Prescription | 26 Jan 2001 |
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | NEPHRON | Prescription | 27 Sep 2001 |
| IPRATROPIUM BROMIDE | 0.021MG/SPRAY | spray, metered · nasal | BAUSCH | Prescription | 31 Mar 2003 |
| IPRATROPIUM BROMIDE | 0.042MG/SPRAY | spray, metered · nasal | BAUSCH | Prescription | 31 Mar 2003 |
| IPRATROPIUM BROMIDE | 0.042MG/SPRAY | spray, metered · nasal | APOTEX INC | Prescription | 18 Apr 2003 |
| IPRATROPIUM BROMIDE | 0.021MG/SPRAY | spray, metered · nasal | APOTEX INC | Prescription | 18 Apr 2003 |
| IPRATROPIUM BROMIDE | 0.042MG/SPRAY | spray, metered · nasal | HIKMA PHARMS | Prescription | 5 Nov 2003 |
| IPRATROPIUM BROMIDE | 0.021MG/SPRAY | spray, metered · nasal | HIKMA PHARMS | Prescription | 5 Nov 2003 |
| ATROVENT HFA | 0.021MG/INH | aerosol, metered · inhalation | BOEHRINGER INGELHEIM | Prescription | 17 Nov 2004 |
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | LUOXIN AUROVITAS | Prescription | 27 Oct 2016 |
| IPRATROPIUM BROMIDE | 0.021MG/SPRAY | spray, metered · nasal | AMNEAL | Prescription | 16 Aug 2022 |
| IPRATROPIUM BROMIDE | 0.042MG/SPRAY | spray, metered · nasal | AMNEAL | Prescription | 16 Aug 2022 |
| IPRATROPIUM BROMIDE | 0.042MG/SPRAY | spray, metered · nasal | RUBICON RESEARCH | Prescription | 15 Nov 2024 |
| IPRATROPIUM BROMIDE | 0.021MG/SPRAY | spray, metered · nasal | RUBICON RESEARCH | Prescription | 14 Jan 2025 |
| IPRATROPIUM BROMIDE | 0.042MG/SPRAY | spray, metered · nasal | LUPIN | Prescription | 27 Jan 2025 |
| IPRATROPIUM BROMIDE | 0.021MG/SPRAY | spray, metered · nasal | LUPIN | Prescription | 7 Feb 2025 |
| IPRATROPIUM BROMIDE | 0.021MG/INH | aerosol, metered · inhalation | ARMSTRONG PHARMS | Prescription | 23 Feb 2026 |
| ATROVENT | 0.018MG/INH | aerosol, metered · inhalation | BOEHRINGER INGELHEIM | Discontinued | 29 Dec 1986 |
| ATROVENT | 0.02% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · inhalation | BOEHRINGER INGELHEIM | Discontinued | 29 Sep 1993 |
| ATROVENT | 0.021MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | spray, metered · nasal | BOEHRINGER INGELHEIM | Discontinued | 20 Oct 1995 |
| ATROVENT | 0.042MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | spray, metered · nasal | BOEHRINGER INGELHEIM | Discontinued | 20 Oct 1995 |
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | PHARMOBEDIENT | Discontinued | 10 Jan 1997 |
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | ACTAVIS MID ATLANTIC | Discontinued | 22 Apr 1999 |
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | TEVA PHARMS USA | Discontinued | 7 Feb 2000 |
| IPRATROPIUM BROMIDE | 0.02% | solution · inhalation | ZENNOVA | Discontinued | 19 Jan 2001 |
8 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AA-IPRAVENT | 02126222 | 250 MCG / ML | SOLUTION · INHALATION | AA PHARMA INC |
| ATROVENT HFA | 02247686 | 20 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | BOEHRINGER INGELHEIM (CANADA) LTD LTEE |
| IPRAVENT | 02246084 | 42 MCG / ACT | SOLUTION · NASAL | AA PHARMA INC |
| JAMP IPRATROPIUM HFA | 02542587 | 20 MCG / ACT | AEROSOL (METERED-DOSE) · INHALATION | JAMP PHARMA CORPORATION |
| PMS-IPRATROPIUM | 02231135 | 125 MCG / ML | SOLUTION · INHALATION | PHARMASCIENCE INC |
| PMS-IPRATROPIUM | 02231244 | 250 MCG / ML | SOLUTION · INHALATION | PHARMASCIENCE INC |
| PMS-IPRATROPIUM | 02231245 | 250 MCG / ML | SOLUTION · INHALATION | PHARMASCIENCE INC |
| PMS-IPRATROPIUM | 02239627 | 21 MCG / ACT | SOLUTION · NASAL | PHARMASCIENCE INC |
| TEVA-IPRATROPIUM STERINEBS | 02216221 | 250 MCG / ML | SOLUTION · INHALATION | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | ATROVENT 17 MCG HFA INHALER | $22.76435 | per GM | 23 Sep 2026 |
| US NADAC | IPRATROPIUM 0.03% SPRAY | $0.36783 | per ML | 23 Sep 2026 |
| US NADAC | IPRATROPIUM 0.06% SPRAY | $0.77751 | per ML | 23 Sep 2026 |
| US NADAC | IPRATROPIUM BR 0.02% SOLN | $0.10402 | per ML | 23 Sep 2026 |
| US NADAC | IPRATROPIUM BR 0.02% SOLN | $0.1122 | per ML | 23 Sep 2026 |
| US NADAC | IPRATROPIUM BR 0.02% SOLN | $0.1099 | per ML | 23 Sep 2026 |
| US NADAC | IPRATROPIUM BR 17 MCG HFA INH | $22.10952 | per GM | 23 Sep 2026 |
| NHS Drug Tariff | Ipratropium bromide 20micrograms/dose inhaler CFC free | £5.56 | 200 dose | 1 Oct 2026 |
| NHS Drug Tariff | Ipratropium bromide 21micrograms/dose nasal spray | £8.72 | 240 dose | 1 Oct 2026 |
| NHS Drug Tariff | Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | £10.05 | 20 unit dose | 1 Oct 2026 |
| NHS Drug Tariff | Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | £7.03 | 20 unit dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Chronic obstructive pulmonary disease; Asthma
Respiratory > Inhalation > solution: 20 µg per actuation in pressurized metered dose inhaler
Safety signals and safety-related labeling changes
- US FDA 27 Sep 2020 COMBIVENT RESPIMAT — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 10 Jan 2020 ATROVENT HFA — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Ipratropium
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.